News reports recently highlighted concerns over the prevalence of the Human Metapneumovirus (HMPV) cases. The UK Health Security Agency (UKHSA) reported a Human Metapneumovirus (hMPV) positivity rate of 4.9% in its surveillance data for the week ending 19 January 2025.
This figure was highlighted in the National Flu and Covid-19 Surveillance Report published on 23 January 2025, indicating a notable increase in HMPV cases during that period.
Subsequent data from the UKHSA dashboard shows a decline in HMPV positivity rates, with figures decreasing to 2.8% by the week beginning 5 May 2025. This trend suggests that the earlier surge in HMPV cases has subsided.
However, while the UK is not on high alert concerning the virus, the incidents of HMPV have drawn comparisons to Covid-19 due to overlapping symptoms and the heightened public sensitivity to respiratory illnesses.
However, while both viruses can cause respiratory infections and circulate more aggressively in colder months, they differ significantly in origin, behaviour, severity, and public health implications.
Origins and Classification
HMPV is a member of the Pneumoviridae family and was first identified in 2001, although evidence suggests it has been circulating in humans for decades. It is a single-stranded RNA virus closely related to respiratory syncytial virus (RSV).
Covid-19, on the other hand, is caused by the novel coronavirus SARS-CoV-2, a member of the Coronaviridae family, which was first identified in 2019 in Wuhan, China. The two viruses are genetically and virologically distinct, with different modes of replication and immune system responses.
Both HMPV and Covid-19 affect the respiratory tract and can present with similar symptoms such as cough, fever, nasal congestion, shortness of breath, and fatigue. However, Covid-19 is more likely to cause a broader range of systemic symptoms, including loss of taste or smell, gastrointestinal issues like diarrhea, muscle aches, and in some cases, long-lasting complications known as ‘long Covid’. HMPV tends to remain more localised to the upper and lower respiratory tract and rarely causes symptoms outside the lungs.
While both viruses pose heightened risks for the elderly, very young children, and those with pre-existing conditions, HMPV particularly impacts infants and the elderly. Severe HMPV infections are a major cause of bronchiolitis and pneumonia in children under five and can exacerbate chronic lung or heart disease in older adults. Covid-19, although similarly dangerous to these groups, has demonstrated a more unpredictable range of outcomes across broader age brackets, especially in unvaccinated populations.
Transmission and Contagiousness
Covid-19 is generally more contagious than HMPV. It spreads rapidly through airborne particles and aerosols, which can linger in the air for extended periods, especially in enclosed or poorly ventilated spaces. HMPV transmission, while also via respiratory droplets and contact with contaminated surfaces, tends to be less aggressive.
As a result, Covid-19 led to a global pandemic and required unprecedented containment measures, while HMPV, despite being seasonal and recurrent, has never approached the same scale of outbreak.
Simply, HMPV does not present the same level of threat as Covid-19. HMPV is a known seasonal virus with relatively predictable behavior. Covid-19, by contrast, caused global disruption, with waves of new variants, lockdowns, and long-term societal impacts.
Public health authorities continue to monitor HMPV closely, but there is currently no indication that it could escalate into a pandemic or require large-scale interventions.
Responding With Context, Not Panic
Although Human Metapneumovirus and COVID-19 can appear similar at first glance, they are fundamentally different in their virology, impact, and the level of public health response they require.
HMPV is a long-standing respiratory virus that follows a seasonal pattern, while Covid-19 reshaped global health policy with its high transmission rate and systemic effects.
Understanding these distinctions is key to interpreting health warnings, taking appropriate precautions, and responding with context, not panic, to rising case numbers.
The UKHSA continues to monitor hMPV and other respiratory viruses through its weekly surveillance reports. Public health officials recommend standard preventive measures, such as regular handwashing, wearing masks in crowded indoor spaces, and staying home when experiencing respiratory symptoms, to reduce the spread of infections.
To manage the surge, public health agencies have issued a series of recommendations to help curb the spread of HMPV. The public is advised to wear face coverings in crowded or poorly ventilated indoor spaces, wash hands frequently with soap and water, and avoid close contact with individuals exhibiting cold or flu-like symptoms. People experiencing symptoms themselves are urged to stay home, rest, and avoid exposing others, particularly those who are most vulnerable.
These precautions are familiar to most from the Covid-19 pandemic, and authorities hope that reinforcing these measures will help reduce not only HMPV transmission but also the overall burden of respiratory infections during the winter months.